Perfluorocarbon as an adjuvant for tumor anti-angiogenic therapy: Relevance to hypoxia and HIF-1.
Angiogenesis
Antiangiogenic therapy
Cancer stem cell
HIF
Perfluorocarbon
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
24
08
2020
revised:
15
10
2020
accepted:
23
10
2020
pubmed:
20
11
2020
medline:
15
5
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
Lack of vascularization results in increased demand for oxygen and creates a defined feature of the tumor microenvironment known as tumor hypoxia. It is well established that in response to hypoxia, hypoxia-inducible factor-1 α (HIF-1α) is induced which is an important factor in angiogenesis, invasion and metastasis. In turn, HIF-1α regulates the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF). Ascribed to abnormal characteristics of tumor angiogenic networks, antiangiogenic therapy approaches can even worsen the hypoxic condition and can create cancer cells with stemness features. Hence oxygen delivery via perfluorocarbon (PFC) to hypoxic sites seems to result in unstable HIF expression and consequent inactivation of angiogenesis cascade and metastasis and therefore, inhibition of cancer cells stemness.
Identifiants
pubmed: 33208240
pii: S0306-9877(20)33248-5
doi: 10.1016/j.mehy.2020.110357
pii:
doi:
Substances chimiques
Fluorocarbons
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110357Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.